Psychedelic decriminalization: perceptions in a 163-person survey

Related Articles

Psiconáutica Editorial Team · September 10, 2026

In brief

  • A survey of 163 people in different decriminalization jurisdictions, including locations in the US, Canada and Europe finds perceived improvements in safety, access to therapy, and well-being.
  • 84% report improvements in at least one use-related domain and 5.5% some worsening. The text reports no increased legal risk, but Table 3 lists one case (0.6%); that discrepancy remains unresolved here.
  • This is a convenience sample, self-reported and without a control group: it does not allow for claims of cause and effect.
Read more  Low-dose psilocybin: a phase 1 trial in 56 healthy adults

A community survey among people who use psychedelics in jurisdictions across several countries, including locations in California, Colorado and Michigan,finds that the majority perceive improvements in safety, access to therapeutic support, and their overall lives since criminal prosecution ceased to be the norm. The study, authored by Daniel J. Kruger, Julie Barron, and Larry Norris in the journal Social Sciences, is among the first to attempt to quantify what happens on the ground when a city council stops prosecuting the possession of mushrooms, ayahuasca, or mescaline.

What was asked and to whom

The team collected 163 valid responses from people who use psychedelic substances and reside in countries, states or municipalities with eligible decriminalization policies, a movement that began in Denver in 2019 and has since spread to dozens of cities and states like Oregon and Colorado. The sample was recruited via convenience, through networks and organizations within the psychedelic community itself, and the authors acknowledge the bias: the profile is predominantly white (78.5%), college-educated, and experienced with frequent use. It is not a snapshot of the general population, but rather of those already involved in the community.

What people living under decriminalization say

84% of respondents noted improvements in at least one of these aspects: legal risk, social acceptance, availability, substance safety, product variety, or quality. Only 5.5% perceived any worsening, and the text states no increased legal risk, although Table 3 lists one case (0.6%); neither account is assumed to be the error. 74.8% perceived improvement in at least one psychedelic-therapy domain, including acceptance, availability, legal risk, safety and service diversity and 72.4% in their general living conditions, compared to 2.5% who perceived a decline. About half reported less stress and anxiety and a greater sense of community; more than a third reported improvements in depressive symptoms and their relationships. A finding of interest to those who follow harm reduction: more than 27% claimed to have stopped or reduced their use of conventional medication, a figure that should be interpreted with caution as it is based on self-reporting rather than medical follow-up. The survey also recorded a shift in how material is obtained, with more home cultivation, more online purchasing, and more physical storefronts—a trade that decriminalization ordinances usually do not authorize and which comes with its own risks: one in five respondents said they had been scammed at least once while purchasing.

Read more  PIVOT: psilocybin trial in veterans with an active comparator

What it implies

The researchers themselves highlight the limitations: it is a cross-sectional survey, without a control group, using a small, self-selected sample of people already favorable to these substances. It does not establish a cause-and-effect relationship, only a perception. Barron further explains why they relied on a survey rather than official records: tracking emergency room visits or 911 calls related to psychedelics is nearly impossible because they are not coded as such, but rather fall into a generic drug category. Nevertheless, the pattern aligns with what harm reduction organizations have maintained for years: when the fear of police decreases, people speak more candidly about their use, seek help sooner, and access support with fewer barriers. It is one more data point, not definitive proof, in a country where dozens of different local policies coexist while federal law remains stagnant.

Source

Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.

Read more  Psilocybin and post-Lyme symptoms: a 20-patient open-label pilot

More on this topic

Comments

Advertisementspot_img

Popular stories